Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Oncimmune Holdings ( (GB:ONC) ) has shared an announcement.
Oncimmune Holdings reported a 138% increase in revenue for FY2024, reaching £2.7 million. Despite industry challenges, such as budget cuts in the pharma sector, the company has maintained a high proportion of repeat business and completed significant operational restructuring, including converting debt into equity and securing new management to focus on its ImmunoINSIGHTS platform. With expectations for revenue growth in FY2025, boosted by significant contract wins, Oncimmune is well-positioned for future expansion, though it remains cautious of potential market volatility.
More about Oncimmune Holdings
Oncimmune is a precision medicine company that specializes in analyzing immune interactions through autoantibody profiling. They partner with global pharmaceutical and biotech companies to discover novel biomarkers for more targeted therapies in immune-mediated diseases. Oncimmune is headquartered in the UK with facilities in Germany and business development teams in the US and Europe.
YTD Price Performance: -36.59%
Average Trading Volume: 167,698
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £10.17M
See more insights into ONC stock on TipRanks’ Stock Analysis page.
